AbbVie Outgrew the Humira Cliff. The Stock Already Knows It.

Israel "Izzy" Englander's Millennium Management reportedly more than doubled its AbbVie stake, and the stock now sits a few dollars below its 52-week high. For a retail investor who learned AbbVie as "the company that lost Humira," that pairing is easy to misread. The useful question is not whether a billionaire is right. It is whether the story that beat this stock down for years is actually over — and, if so, whether the market has already charged you for knowing it.

The old fear, restated

For a decade, AbbVie's identity was Humira, the world's best-selling drug. The entire bear case was one slow-motion event: the day Humira lost U.S. patent exclusivity in 2023 and biosimilars rushed in. Investors priced years of falling revenue into the stock in advance, and the shares famously lagged even as the company kept compounding.

That fear was rational once. It is the "old story" this company has spent three years outgrowing. The question is what the numbers have done since.

The hand-off is already in the numbers

The single fact that collapses the old story is this: Skyrizi and Rinvoq, the two next-generation immunology drugs, now generate more in combined sales than Humira did at its peak. In Q1 2026, Skyrizi grew 30.9% to $4.48 billion and Rinvoq grew 23.3% to $2.12 billion, while Humira collapsed 38.6% to $688 million. Through it all, total revenue still grew. The company has said the newer drugs will be the main growth driver of the post-Humira era.

The re-rating shows up at the aggregate level too: AbbVie's full-year 2026 adjusted earnings guidance was raised to $14.08–$14.28 per share after the first quarter beat, and Q2 revenue came in at $16.99 billion, up 10.2% year over year, with adjusted EPS up 22.9% to $3.65.

This is where free cash flow does the real work. Over the trailing twelve months, AbbVie generated about $18.2 billion of free cash flow — roughly a 32% cash-flow margin on revenue. That is not a hope-based story. It is a business converting a third of every sales dollar into cash after funding everything it needs, and it is what actually funds a dividend AbbVie has raised for twelve consecutive years, currently yielding about 2.6%.

The operating fear that defined the old story — Humira erosion hollowing out the company — is no longer visible in the cash-flow path. The transition happened underneath the market's old pricing.

The catch: the market already knows

Here is where AbbVie stops being a classic version of the setup I usually hunt for. That setup relies on the market still pricing the old risk while the operating path improves — a beat-down, hated entry. That is not AbbVie right now. The stock is up roughly 25% over the past four months and about 12.5% year to date, and it trades within a few percent of its 52-week high. The expectation reset ran its course; this is not an unloved name anymore.

You can see that in the price/cash-flow math. At a market cap around $454 billion against that $18.2 billion of trailing free cash flow, the stock trades at roughly 25 times cash flow. That is not a depressed multiple, and it is not the "illusion of control" of a complex model — it is just ordinary arithmetic. It means the bull case from here is no longer "cheap and misunderstood." It is "expensive but still growing double digits while paying you 2.6% to wait."

And there is one wrinkle worth being honest about. Revenue is growing at double digits, but trailing free cash flow is essentially flat year over year. So the rerating is not being pulled by a rising cash-flow stream yet — it is being pulled by the revenue and profit acceleration, and by the market finally believing it. For AbbVie to earn today's ~25 times cash flow, that growth needs to start flowing through to free cash flow, not just to reported earnings.

What would prove the new story wrong

Every thesis needs a tripwire, and here it is plain. The new story is: the growth portfolio has permanently replaced Humira. It breaks if Skyrizi and Rinvoq stop growing while Humira keeps eroding — if the double-digit revenue growth stalls and the free cash flow stays flat instead of turning up. Watch the growth rates of the two immunology drugs and whether free cash flow starts rising with the revenue. If those hold, the old Humira story is genuinely dead and the debate is only about price. If they decouple, yesterday's fear becomes today's valuation problem.

None of this says to chase a stock at a 52-week high. It says the reason AbbVie was cheap and unloved — the Humira cliff — is behind it, and a well-paid, cash-generative business is what's left. Whether Englander's doubled stake is a signal and whether you should buy are different questions; the numbers answer the first, and only the price decides the second. This is not about excitement. It is about a business that has already stopped being easy to dismiss — and a stock that may already reflect it.